Journal
JOURNAL OF VIROLOGY
Volume 90, Issue 1, Pages 180-188Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/JVI.02342-15
Keywords
-
Categories
Funding
- HHS \ National institutes of Health (NIH) [CA138213, RR15635]
- National Multiple Sclerosis Society (NMSS) [PP3446]
- DOD \ Congressionally Directed Medical Research Programs (CDMRP) [W81XWH-12-1-0225]
Ask authors/readers for more resources
Kaposi's sarcoma (KS)-associated herpesvirus (KSHV) is a human gammaherpesvirus associated with several human malignancies. The replication and transcription activator (RTA) is necessary and sufficient for the switch from KSHV latency to lytic replication. Interleukin 1 (IL-1) is a major mediator for inflammation and plays an important role in both innate and adaptive immunity. Myeloid differentiation primary response gene 88 (MyD88) is an essential adaptor molecule for IL-1 as well as most Toll-like receptor signaling. In this study, we identified a novel mechanism by which KSHV interferes with host inflammation and immunity. KSHV RTA specifically reduces the steady-state protein levels of MyD88, and physiological levels of MyD88 are downregulated during KSHV lytic replication when RTA is expressed. The N-terminal region of RTA is required for the reduction of MyD88. Additional studies demonstrated that RTA targets MyD88 expression at the RNA level, inhibits RNA synthesis of MyD88, and may bind MyD88 RNA. Finally, RTA inhibits IL-1-mediated activation of NF-kappa B. Because IL-1 is abundant in the KS micro-environment and inhibits KSHV replication, this work may expand our understanding of how KSHV evades host inflammation and immunity for its survival in vivo.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available